On Oct 19, major Wall Street analysts update their ratings for $Elevance Health (ELV.US)$, with price targets ranging from $520 to $622.
BofA Securities analyst Joanna Gajuk initiates coverage with a hold rating.
Barclays analyst Andrew Mok CFA maintains with a buy rating, and maintains the target price at $622.
UBS analyst A.J. Rice maintains with a buy rating, and adjusts the target price from $605 to $555.
Truist Financial analyst David S Macdonald maintains with a buy rating, and sets the target price at $520.
Argus Research analyst David Toung initiates coverage with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Elevance Health (ELV.US)$'s main analysts recently are as follows:
Post the Q3 report, Medicaid pressures are overshadowing the positive developments in the company's commercial and Carelon divisions.
Following Elevance Health's third-quarter earnings shortfall and revised guidance, shares experienced a downturn. This was a reaction to management reducing the 2024 EPS outlook, citing larger than expected Medicaid headwinds. Despite these developments, the long-term perspective remains stable, with the current Medicaid mix challenges viewed as a short-term issue.
Here are the latest investment ratings and price targets for $Elevance Health (ELV.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
